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Background. The use of resequencing microarrays for screening multiple, candidate disease loci is a promising alternative to
conventional capillary sequencing. We describe the performance of a custom resequencing microarray for mutational analysis
of Congenital Myasthenic Syndromes (CMSs), a group of disorders in which the normal process of neuromuscular transmission
is impaired. Methodology/Principal Findings. Our microarray was designed to assay the exons and flanking intronic regions
of 8 genes linked to CMSs. A total of 31 microarrays were hybridized with genomic DNA from either individuals with known
CMS mutations or from healthy controls. We estimated an overall microarray call rate of 93.61%, and we found the percentage
agreement between the microarray and capillary sequencing techniques to be 99.95%. In addition, our microarray exhibited
100% specificity and 99.99% reproducibility. Finally, the microarray detected 22 out of the 23 known missense mutations, but
it failed to detect all 7 known insertion and deletion (indels) mutations, indicating an overall sensitivity of 73.33% and
a sensitivity with respect to missense mutations of 95.65%. Conclusions/Significance. Overall, our microarray prototype
exhibited strong performance and proved highly efficient for screening genes associated with CMSs. Until indels can be
efficiently assayed with this technology, however, we recommend using resequencing microarrays for screening CMS
mutations after common indels have been first assayed by capillary sequencing.
Citation: Denning L, Anderson JA, Davis R, Gregg JP, Kuzdenyi J, et al (2007) High Throughput Genetic Analysis of Congenital Myasthenic Syndromes
Using Resequencing Microarrays. PLoS ONE 2(9): e918. doi:10.1371/journal.pone.0000918
INTRODUCTION
Congenital myasthenic syndromes (CMSs) comprise a distinctive
group of disorders in which the normal process of neuromuscular
transmission is impaired by one or more pathogenic mechanisms.
To date, nine genes have been demonstrated to harbor causative,
mostly recessive, mutations for CMSs (Table 1; [1–8]). In the
majority of these cases, patients present as compound hetero-
zygotes, usually combining a missense mutation in one allele with
a missense, nonsense, or frameshift mutation in the other allele of
the same gene [4]. Other less frequent defects involve splice
junctions [9], promoter regions [10], chromosomal micro-
deletions [11], and intronic areas outside the splice junction
consensuses [12]. In addition, with few exceptions, mutations
responsible for CMSs are private, so that considerable effort is
required to detect the mutation or mutations present in each
individual. Furthermore, only a few phenotypic clues can point
to mutations in one or a limited number of genes [13]. In
the absence of these clues, determining the exact genetic causes
of CMS in each patient requires that all genes linked to CMSs
be amplified and sequenced, a labor and time-intensive un-
dertaking. Thus, there is a real need for a high-throughput
technique to efficiently screen the DNA sequences of genes
associated with CMSs.
Sequence analysis based on custom resequencing microarrays
has recently emerged as a powerful strategy for screening
mutations in multiple genes linked to a common phenotype
[14–16]. This report describes our design and evaluation of
a resequencing microarray for mutational analysis of CMSs.
We find that with respect to the detection of missense
mutations, our microarray performs well. Moreover, it exhibits
high specificity and reproducibility. However, this technology
is not able to efficiently assay indels. We therefore suggest
that resequencing microarrays be employed for mutational
analysis after common indels have been screened by capillary
sequencing.
METHODS
Resequencing Microarray Design
Our microarray was designed to sequence all exons and 8 base
pairs (bp) of flanking intronic regions from the splice junctions of
CHRNA1, CHRNB1, CHRND, RAPSN, COLQ, CHAT, and MUSK
(Table 1). Additionally, 250 bp of the RAPSN and CHRNE
promoter regions as well as the entire genomic sequence of
CHRNE were tiled on the microarray. These latter sequences were
added because promoter mutations and exonic mutations have
been reported in RAPSN [5], [14], and promoter, exonic, and
intronic mutations have been reported in CHRNE [5], [10], [12].
The sequence for each gene was obtained from GenBank (see
Table S1) and subjected to Repeat Masker (Institute for Systems
Biology, Seattle, WA), a program that identifies repetitive elements
(e.g. SINEs, LINEs, and ALUs) and internal duplications. In
addition, because the association between CMS and DOK7
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not included in the microarray (Table 1).
Subjects
The sensitivity of the microarray was determined using DNA from
21 CMS patients possessing mutations previously characterized by
capillary sequencing. In addition, both the specificity and
reproducibility of the microarray were determined using DNA
from 5 healthy individuals. This study was approved by the
Institutional Review Board of the University of California, Davis.
All subjects were informed of their rights and the details of the
research, and they all signed an ‘informed consent’ form.
DNA extraction and PCR
DNA was extracted from blood samples using the QIAamp DNA
Blood Mini Kit (Qiagen, Valencia, CA). We used a combination of
traditional PCR and long distance PCR to reduce the overall
number of reactions required. The size of the PCR amplicons
ranged from 170 bp to nearly 13 kb. All primers were designed
using Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3
_www.cgi). Primer sequences and reaction conditions are available
upon request.
A 7.5 kb plasmid (IQ-EX) included in the manufacturer’s assay
(GeneChipH Resequencing Assay Kit, Affymetrix, Santa Clara,
CA, USA) was amplified according to the manufacturer’s
instructions and was used as a positive internal control.
Quantitation, pooling, fragmentation, and labeling
of products
The PCR products were purified of residual reagents using a PCR
purification kit (Qiagen) according to the manufacturer’s instruc-
tions. The DNA concentration of each purified product was
measured (ng/ml) (NanoDrop Technologies, Wilmington, DE).
After calculating the molarity of each sample, equimolar amounts
of the products were pooled to achieve even hybridization across
the microarray.
The MicroArray Core Facility at the UC Davis Medical Center
(Sacramento, CA) M.I.N.D. Institute performed all of the
experimental procedures for the arrays. The pooled PCR products
were fragmented using Fragmentation Reagent (0.15U Dnase
We/ug DNA, GeneChipH Resequencing Assay Kit, Affymetrix) at
37uC for 15 minutes, followed by inactivation at 95uC for
15 minutes. Pooled and fragmented PCR products were end-
labeled using a biotin-labeling reagent (GeneChipH DNA Labeling
Reagent, 5 mM, Affymetrix) and terminal deoxynucleotidyl
transferase (TdT, Affymetrix) at 37uC for 2 hours, followed by
inactivation at 95uC for 15 minutes. The amplified plasmid
control (IQ-EX) was fragmented and labeled for use in the
hybridization cocktail.
Microarray Hybridization and Analysis
Hybridization was performed according to the manufacturer’s
protocol. The microarrays were placed in a Hybridization Oven
640 (Affymetrix) at 45uC for 16 hours, rotating at 60 RPM. The
arrays were then washed and stained on a fluidics station using the
manufacturer’s wash and stain protocol (DNAAR-
RAY_WS4_450). They were subsequently scanned on a Gene-
ChipH 3000 Scanner (Affymetrix), and the data from each scan
were analyzed using GeneChipH Resequencing Analysis Software,
Version 4.0 (GSEQ v4.0, Affymetrix). See Figure 1 for an example
of the software output.
This software uses an algorithm based on the Adaptive
Background genotype Calling Scheme (ABACUS) created by
Cutler et al. (2001; [18]). The algorithm allows for 11 possible
models: A, C, G, T, AC, AG, AT, CG, CT, GT, and no-call (N).
It calculates the likelihood of each model representing the
observed data independently for the forward and reverse strands
of each position, and it uses these data to calculate an overall
likelihood of a particular model fitting the data for that position.
There are three results that can arise from the overall likelihood
calculation for a particular site: a near perfect fit where the
forward and reverse strand fit the same model, an imperfect fit
where data from one strand fit the model well but data from the
other do not, or a no-call where no model fits the data from either
strand. Once an initial call is made, the data must fit reliability
rules to ensure the data are reliable; the user has control over
certain settings of the reliability rules. A final call is then made for
each position. Because some of the reliability rules require that
data from each sample be compared to data from other samples at
the same position, it is recommended that a minimum of 15
microarrays be analyzed together for optimal algorithm perfor-
mance.
Capillary Sequencing
To initially identify the mutations carried by each patient as well as
to estimate the percentage agreement between the capillary and
microarray sequencing techniques, DNA was amplified as pre-
viously described and then sequenced at the UC Davis Division of
Table 1. Genes associated with congenital myasthenic syndromes.
..................................................................................................................................................
Gene Symbol Protein location Genomic location Genomic size (bp)
Assayed region
size (bp)
Choline acetyltransferase CHAT presynaptic 10q11.2 56,009 3458
Collagen-like tail subunit of asymmetric
acetylcholinesterase
COLQ synaptic 3p16.2 71,618 3566
Acetylcholine receptor, alpha subunit CHRNA1 postsynaptic 2q24-q32 16,861 2019
Acetylcholine receptor, beta subunit CHRNB1 postsynaptic 17p13.1 12,526 1977
Acetylcholine receptor, delta subunit CHRND postsynaptic 2q33-q34 9,283 2210
Acetylcholine receptor, epsilon subunit CHRNE postsynaptic 17p13-p12 5,308 5598
Receptor-associated protein of the synapse RAPSN postsynaptic 11p11.2-p11.1 11,413 2227
Muscle skeletal receptor tyrosine kinase MUSK postsynaptic 9q31.3-q32 132,139 3252
Downstream-of-kinase 7 DOK7 postsynaptic 4p16.2 31,170 Not included
doi:10.1371/journal.pone.0000918.t001
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PLoS ONE | www.plosone.org 2 September 2007 | Issue 9 | e918Biological Sciences DNA Sequencing Facility (Davis, CA) using an
ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA).
Analysis
The sensitivity of the microarray methodology with respect to the
known pathogenic mutations was defined as the proportion of true
positives detected by the microarray, while the specificity was
defined as the proportion of true negatives detected. Additionally,
the reproducibility was defined as the proportion of identical calls
made across the five microarrays assayed with identical DNA.
Finally, the percentage agreement between the microarray data
and the data produced by capillary sequencing represents the
proportion of identical calls between the two methods.
RESULTS
Design of the microarray
Screening with RepeatMasker indicated that no repetitive
elements or internal duplications were present in the regions
resequenced by the microarray. The total number of base pairs
resequenced by the microarray was 24,056; 22,214 bp represented
genomic sequence covering the eight genes included in the array,
and 1,842 bp corresponded to common mutations tiled in
duplicate (Tables 1 and 2). An 814 bp internal control, represent-
ing the 7.5 kb plasmid control (IQ-EX) provided by the
manufacturer was also tiled on the microarray as a means of
evaluating individual microarray performance. The microarrays
were designed with 25 by 20 micron feature size.
Sequencing with the CMS1 microarray
DNA from 26 individuals (21 patients and 5 controls) was
sequenced, and for one control, an additional five microarrays
were used to determine the reproducibility of the resequencing
data. Therefore, a total of 745,736 bases were sequenced across
the 31 arrays (21 patient arrays and 10 control arrays; Table 2).
The sequence analysis software assigned calls to 698,059 of these
bases for an overall call rate of 93.61% (Table 2). Call rates for
individual microarrays varied from 92.14%–94.87%. The median
GC content of sites assigned a no-call designation (N) for all
microarrays was 66%, while the GC content of the entire sequence
tiled on the microarray was 57%, a significant difference (p,0.01,
t-test). A significant negative correlation was also detected between
GC content and the median call rate (R
2=0.0873, p,0.01; see
Figure 2).
Findings in patients
According to the capillary sequence data, the 21 patients in this
study exhibit a total of 30 mutations, including 23 missense, 4
insertion, and 3 deletion mutations (Table S2). The microarray
was able to detect 22 of the missense mutations and none of the
insertion or deletion mutations (Table S2). Of the 21 patients, 13
were accurately detected as positive for their respective mutations.
All 13 patients were either homozygous or heterozygous for
missense mutations. Four additional patients carried one missense
mutation and one insertion or deletion mutation, and the missense
mutations in these four patients were accurately detected. Three of
Figure 1. Conversion of microarray probe intensities into sequence by GSEQ v4.0: an illustration of software output. A. A digital color image of
the scanned data for the entire microarray. The sense and antisense strands of the DNA fragment are highlighted. B. A close-up view of part of the
sense strand highlighted in A. C. The converted sequence displayed in B. D. Probe intensity of the heterozygous site at position 52 shown in C.
doi:10.1371/journal.pone.0000918.g001
Table 2. Summary of the microarray data.
......................................................................
Number of base pairs analyzed per chip 24,056
Total number of arrays analyzed 31
Total number of base pairs called by GSEQ 698,059
Overall call rate 93.6%
Overall sensitivity 73.3%
Sensitivity to missense mutations 95.6%
Specificity 100%
Number of chips analyzed for reproducibility 5
Number of base pairs analyzed for reproducibility 113,474
Number of discrepant sites detected among reproducibility chips 1
Overall reproducibility 99.996%
doi:10.1371/journal.pone.0000918.t002
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PLoS ONE | www.plosone.org 3 September 2007 | Issue 9 | e918the 21 patients carried one or two insertion or deletion mutations,
none of which was detected by the microarray. Finally, one of the
21 patients was heterozygous for a missense mutation which was
not detected by the microarray (Table S2). Overall, the sensitivity
of the microarray was estimated to be 73.3%, while the sensitivity
of the microarray with respect to missense mutations was
estimated to be 95.65% (22/23 detected; Table 2).
Findings in controls
No pathogenic mutations were detected among the five healthy
controls in this study, even though multiple SNPs were detected.
Interestingly, a unique nonsynonymous variant was found in
a single healthy control. This variant causes an arginine to
tryptophan replacement (at site 22 of the amino acid sequence)
and was confirmed by capillary sequencing. Although this is
a highly conserved residue across mammals, there is no indication
this mutation is pathogenic, and the individual was considered to
have been correctly identified as a true healthy control. As a result,
the specificity of the microarray was 100% (Table 2).
To assess the reproducibility of the microarray approach, five
microarrays were hybridized to DNA from the same individual.
Calls were assigned to 113,474 of the 120,280 tiled bases, yielding
an overall call rate of 94.34% (Table 2). Call rates for each of the
five microarrays varied from 93.81%–94.97%, and the average
number of calls per microarray was 22,695 out of 24,056. A single
discrepancy was found among the five microarrays: two of the
microarrays were called ‘G ’, matching the reference sequence,
two others were called heterozygotes for ‘A’ and ‘G’, and the last
microarray showed a no-call in this position. One discrepancy
among an average of 22,695 base calls yielded a reproducibility
estimate of 99.996% (Table 2).
SNPs and comparison between techniques
Heterozygosity estimates have revealed that, on average, SNPs
occur at a frequency of 1 in every 1000 bases across the human
genome [17]. For this study, a total of 102 SNPs were detected by
the microarray, including the 22 missense mutations considered to
be pathogenic (Table 3). Of the 80 remaining SNPs, 37 have been
documented in the GenBank SNP database (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi?db=Snp; see Table S3). Using the
80, nonpathogenic SNPs, the expected heterozygosity (often
referred to as ‘pi’) per site per gene region was estimated (see
Figure 2. Relationship between GC content and call rate. The median call rate of each fragment across all microarrays is plotted against the GC
content of each fragment.
doi:10.1371/journal.pone.0000918.g002
Table 3. Description of SNPs detected.
..................................................................................................................................................
Gene
No. microarray
SNPs
No. discrepant sites/
No. SNPs checked*
No. new
capillary SNPs
Total No.
discrepant sites
Expected
heterozygosity per site
CHRNA1 2 1/2 0 1 0.0002
CHRNB1 7 5/7 0 5 0.0015
CHRND 11 4/11 0 4 0.0009
CHRNE 25 7/21 4 7 0.0009
RAPSN 10 1/9 1 1 0.0007
COLQ 9 1/9 0 1 0.0007
CHAT 10 0/10 0 0 0.0008
MUSK 6 1/6 1 1 0.0005
Total 80 20/75 6 20 0.0008
*A total of 75 of the 80 microarray SNPs were cross-checked via capillary sequencing or electronically through the GenBank SNP database.
doi:10.1371/journal.pone.0000918.t003
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e918Table 3). Although there is variation across gene regions, these
estimates are close to the genome-wide average of ,0.001
(Table 3).
To determine how well sequence data from the microarray
correspond to sequence data from capillary sequencing, 96,686
base calls from across 26 microarrays (21 patients and 5 controls)
were compared to capillary sequence data at the same positions.
This degree of capillary sequencing allowed us to assess agreement
between the two methods for 70 of the 80 SNPs. Of the remaining
10 SNPs, five were verified electronically using the GenBank SNP
database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=
Snp). It remains to be determined whether the remaining five
SNPs are detected by both sequencing approaches.
A total of 20 discrepant sites were found between the
microarray and capillary sequencing data (Table 3). All of these
sites involved SNPs detected by the microarray but not by
capillary sequencing, and seven of the sites were singletons; that is,
they were detected in just a single microarray. Interestingly, six
additional SNPs were detected exclusively by the capillary
sequencing method, one of which was a singleton; we did not
consider these six sites to represent discrepancies, however, as they
were called ‘N’s by the microarray (Table 3). None of the
discrepant sites called by the microarray is documented in the SNP
database, whereas three of the six sites detected by capillary
sequencing are corroborated in the database. Overall, 96,635 of
the 96,686 assayed bases were identical between the two methods.
Therefore, the percentage agreement was 99.947%. However,
with respect to sites segregating for SNPs, the percentage
agreement between these two methods was only 73.3% (55/75
SNPs; these 55 SNPs are reported in Table S3). Despite this
degree of disagreement, estimates of heterozygosity do not change
appreciably when using SNP information from the capillary
sequencing method (data not shown).
For all of the discrepant sites, the raw trace data from
both sequencing techniques were examined. It appears that
many of the SNPs called by the microarray software, but not
by the capillary technique, were in regions of poor data quality
(i.e. several surrounding sites called Ns). In fact, most of
the polymorphisms detected in regions of poor data quality
were not compelling when examining the raw data, and for
many SNP sites, just one of the strands was of good quality
(both strands were sequenced for both methods). However,
for 8 of the 20 total discrepant sites, convincing and contra-
dictory data were found for both techniques. One approach to
addressing this conflict is to employ a third and independent
methodology, such as SSCP (single-stranded conformation poly-
morphism), to re-assay these regions. Alternatively, comparing
only data that are validated by a predetermined quality score
for both techniques may reveal many fewer, if any, discrepancies
[18; see below].
As another approach to assessing the quality of the microarray
data, it was determined whether the 80 SNPs exhibited Hardy-
Weinberg genotype proportions across the sample. Six of the SNPs
were found to deviate significantly from Hardy-Weinberg
expectations (i.e. x
2.3.84, p,0.05). To address this, these six loci
were re-sequenced in all 26 individuals using capillary sequencing.
Overall, departures from Hardy-Weinberg expectations can be
explained by the failure of the microarray software to detect all of
the heterozygous individuals, either because it called these sites
‘Ns’, or because these sites were called homozygous. In fact, when
the genotype proportions provided by the capillary sequence data
are used, these SNPs were all found to be in Hardy-Weinberg
Equilibrium (data not shown).
DISCUSSION
Resequencing microarrays provide a rapid and cost effective
method for screening mutations in genetically heterogeneous
diseases such as CMSs. Indeed, this technique uses many fewer
PCR reactions to amplify and sequence long segments of genomic
DNA, and it assays multiple genes using a single hybridization
reaction. In this study, we were able to analyze more than 24
kilobases of gene regions linked to CMSs from the products of just
35 PCR reactions. In contrast, a capillary sequencing approach
requires greater than 100 PCR reactions. Moreover, our
resequencing microarray exhibited a high degree of sensitivity
with respect to the detection of missense mutations, its average call
rate exceeded the 90% rate guaranteed by the manufacturer, it
was highly reproducible, and it showed a high level of agreement
with the data produced by capillary sequencing.
Although other groups have also reported high performance
from custom resequencing microarrays [14–16], there are
limitations associated with the technology. For example, the call
rate of different resequencing microarray designs may vary
considerably. In fact, studies have reported anywhere from fewer
than 50% of their microarrays achieving a call rate of greater than
90% to nearly 100% of their microarrays achieving a call rate of
97.5% [15], [16]. Importantly, some of this variability can be
explained by differences in the user-chosen settings of the
CustomSeq
TM Algorithm. For example, settings for data filters
that capture features with either minimal intensity or intensity
approaching the saturation level of the detector can be changed by
the user to be more stringent or more relaxed. If the settings are
more relaxed, fewer sites will be assigned as no-calls by the filter,
but the calls made will be less reliable. If the settings are more
stringent, more sites will be assigned as no-calls by the filter and
the overall call rate will be reduced, but calls made will be more
reliable. Depending on the particular microarray as well as the
goals of the study, the optimal set of parameters will vary.
The GC content of a region may also affect the call rate. In fact,
our finding that the call rate of the fragments tiled on our
microarray decreased as the GC content increased (see Figure 2)
corroborates the result of another study, in which 98.4% of the
bases assigned as no-calls were either G or C [14]. It is possible
that GC-rich probes bind more strongly to the target DNA,
thereby increasing the chance of signal saturation and a no-call at
a particular position. Interestingly, Cutler et al. (2001; [18]) found
that fluorescence intensity declines with the G-richness of a probe,
leading to a lower call rate due to the decreased reliability of such
probes. However, another study found no correlation between
probe content and call rates [19]. Clearly, additional data and
analysis are required to understand the relationship, if any,
between these two variables.
Despite the high percentage of agreement found in our study,
the agreement between the microarray and capillary sequencing
techniques with respect to sites segregating for SNPs was only
73.3%. This number is much lower than the overall agreement, in
part, because the level of variation in humans tends to be low (i.e.
there are many more invariant sites; also see Table 3 for
heterozygosity estimates). Consequently, using the microarray
technology for high throughput SNP discovery and genotyping has
been controversial, and efforts have been made to identify the sites
with the highest likelihood of being correct (see [18], and
references therein). As mentioned above, this can be accomplished
by increasing the stringency settings of the calling algorithm [18].
Accompanying an increase in the reliability of each call, however,
is a reduction in the overall call rate. In fact, in their paper
introducing the ABACUS algorithm, Cutler et al. (2001; [18])
found that only ,80% of the sites could be called with these high
Screening with Microarrays
PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e918stringency settings. From our perspective, this may not be an ideal
solution, as it is possible that a mutation will be overlooked when
screening DNA from a patient with an unknown mutation profile.
Such a scenario is of greatest concern for CMS studies when single
heterozygous mutations have dominant effects, as in the case of
slow-channel syndrome or in rare cases of fast-channel syndrome
due to dominant negative mutations [8]. Undoubtedly, the trade-
offs between call rate and call quality will continue to be an
important issue surrounding the use of resequencing microarrays
for mutational analysis.
Another serious limitation of this technology is that it cannot
detect insertion and deletion mutations. This is of particular
concern for mutations in CHRNE and DOK7, which together
account for a large number of CMS patients, and in which indels
are often encountered in the homozygous state. Therefore, we
suggest that resequencing microarrays should be used for
screening CMS mutations after CHRNE and DOK7 have been
screened by capillary sequencing. We hope that the increased
capability of the recently available, more powerful 100K and
300K microarray platforms will allow the inclusion of probes
complementary to common insertions and deletions at each
sequence position to overcome this technological limitation. In
fact, such an approach has recently been shown to be feasible [20].
Alternatively, as reviewed by Hacia (1999; [21]), heterozygous
indels have been successfully detected when using a loss-of-signal
hybridization approach (in contrast to the gain-of-signal approach
used in this study). By definition, this approach can only identify
the presence of indels; however, capillary sequencing can then be
used to determine the actual sequence changes. Clearly, the
technology or combination of technologies with the highest power
of detection will depend on the particular genes being assayed as
well as the goals of the study.
SUPPORTING INFORMATION
Table S1 Genomic Sequences from Genbank.
Found at: doi:10.1371/journal.pone.0000918.s001 (0.04 MB
DOC)
Table S2 Missense and indel mutations carried by the 21
studied patients.
Found at: doi:10.1371/journal.pone.0000918.s002 (0.07 MB
DOC)
Table S3 Information on the 55 validated SNPs (also see
Table 3).
Found at: doi:10.1371/journal.pone.0000918.s003 (0.14 MB
DOC)
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